MindBio Therapeutics Corp.

MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6) has started selection of participants for its phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of lysergic acid diethylamide (LSD) and meaning centered psychotherapy in an...

Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD). MDD is reportedly the leading cause...

Australia-based MindBio Therapeutics Corp., an ex-subsidiary to Blackhawk Corp. received ethics approval for a Phase 2 clinical trial assessing the effects of LSD microdoses, paired with meaning-centered psychotherapy, on patients with advanced-stage cancer. The randomized, double-blind,...

Blackhawk and MindBio Complete Plan Of Arrangement, Shares Spinout Investment holding company Blackhawk Growth Corp. and its psychedelics biotech subsidiary MindBio Therapeutics Corp. have completed the announced plan for the spinout of MindBio common shares. Blackhawk has renamed its common shares...

The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. Blackhawk’s New Arrangement Plan For Three Of Its Businesses Investment holding company Blackhawk...